REVB — REVELATION BIOSCIENCES, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1810560 ·
Last close
$1.06
Market Cap
$4.14M
52W High
$1.43
52W Low
$0.88
ADV30
72,720
Next earnings
2026-08-07
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -3,092,500 | -3,009,051 | 15,044,282 | 14,113,415 | 2,055,329 |
| Dec 2025 | 0 | — | -2,571,588 | -2,511,006 | 11,582,924 | 10,700,331 | 2,721,929 |
| Sep 2025 | 0 | — | -1,943,011 | -1,907,176 | 12,856,342 | 12,708,489 | 1,854,507 |
| Jun 2025 | 0 | — | -2,461,229 | -2,444,382 | 5,395,090 | 5,173,871 | 1,569,306 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-8,269,581
Investing CF
$0
Financing CF
$12,470,894
CapEx
$-17,688
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-118.17
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-49,419,287
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-9,070,815
Pretax Income TTM
$-8,913,649
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -9,070,814 | -8,913,649 | 11,582,924 | 2,721,929 | — | -8,269,581 |
| Dec 2024 | 0 | -7,975,109 | -15,038,536 | 6,622,049 | 1,913,667 | — | -18,321,276 |
| Dec 2023 | 0 | -8,656,664 | -120,254 | 12,212,609 | 5,564,894 | — | -7,286,286 |
| Dec 2022 | 0 | -10,864,511 | -10,829,549 | 5,503,415 | 4,450,962 | — | -11,219,396 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.77
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GLMD | Galmed Pharmaceuticals Ltd. | $4.16M | $0.63 | — |
| XRTX | XORTX Therapeutics Inc. | $4.10M | $2.37 | — |
| MBIO | MUSTANG BIO, INC. | $4.19M | $0.62 | — |
| DCOY | Decoy Therapeutics Inc. | $4.06M | $7.63 | — |
| CDT | CDT Equity Inc. | $4.30M | $0.88 | — |
News headlines (Yahoo Finance, 1h cache)
Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders
2026-05-11 13:00 · Yahoo
REVB Poised for Big Year
2026-05-08 12:04 · Yahoo
Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026
2026-05-07 20:15 · Yahoo
Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board
2026-04-06 13:00 · Yahoo
Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study
2026-03-30 13:00 · Yahoo
REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference
2026-03-24 13:00 · Yahoo
Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference
2026-03-19 13:00 · Yahoo
REVB 2026 Starts in Positive Fashion
2026-02-27 11:12 · Yahoo
Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025
2026-02-26 21:15 · Yahoo
REVB Comes to Agreement with FDA
2026-01-29 10:16 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.